RFK Jr. Announces Plan to Help Wean People Off Antidepressants
RFK Jr. announced a plan to reduce overprescribing of psychiatric medications and support deprescribing when appropriate, with new federal training and Medicare billing changes.
Objective Facts
US Health and Human Services Secretary Robert F. Kennedy Jr. announced a plan to reduce overprescribing of psychiatric medications and support alternative treatment options and discontinuation of medications when needed, stating the effort will address the overuse of psychiatric medications especially among children. The Substance Abuse and Mental Health Services Administration will publish new data on prescribing trends and clinical guidance for providers, the Centers for Medicare & Medicaid Services will issue billing guidance for providers to help patients taper off drugs when they need or want to, and CMS will expand access to alternative forms of evidence-based treatments like talk therapy and family support services for children. In 2025, approximately 16.6% of US adults reported taking an SSRI. The American Psychiatric Association president called RFK Jr.'s framing an oversimplification and mental health advocates and psychiatrists say blaming the United States' mental health crisis on overmedicalization and overprescription is an inaccurate portrayal of a complex problem.
Left-Leaning Perspective
The Mary Sue and other left-leaning outlets criticized Kennedy's plan, highlighting that the HHS press release explicitly mentions concerns about antidepressant use especially among children, but noted a gaping hole: if millions of Americans can't even see a therapist or access specialized care, the proposed holistic solutions of psychotherapy, nutrition, and physical activity don't matter if those options aren't available or affordable. The opinion piece on MS Now argued that as of 2024, 122 million Americans lived in areas with a shortage of mental health providers, with nearly three-quarters of antidepressant prescriptions issued by primary care providers rather than psychiatrists, yet Kennedy would rather blame pharmaceuticals instead of addressing provider shortage issues. The MS Now opinion also contended that deprescribing decisions should be shaped by clinical factors and evidence rather than policy matters concerning how the nation thinks about mental health, and that psychotherapy, improved nutrition and physical activity cannot replace safe and effective medications that correct potentially debilitating neurochemical imbalances.
Right-Leaning Perspective
Fox News reported that Robert F. Kennedy Jr. unveiled an HHS initiative targeting psychiatric medication overuse, promoting non-drug treatments and shifting care toward prevention and holistic approaches, with Kennedy emphasizing appropriate deprescribing of psychiatric drugs. Dr. Allen Frances, former Chair of the Duke University Department of Psychiatry, praised the announcement via X, calling it a miracle and arguing for guidelines to stop careless prescribing and encourage careful deprescribing of what he called the ridiculous 16% rate of antidepressant use in the US. Other right-leaning voices and commentators, including Martin Varsavsky and advocates citing Big Pharma incentives, argued that paying doctors to deprescribe is paying for judgment rather than volume, and represents exactly how primary care should move toward fewer unnecessary pills and better accountability.
Deep Dive
SSRIs gained popularity nearly four decades ago partly because they caused fewer side effects than earlier antidepressants and could be prescribed by general practitioners, and today nearly 17 percent of American adults are taking them, with antidepressant use increasing in most economically developed nations including among children. The American Foundation for Suicide Prevention presents scientific evidence that antidepressants are effective in treating acute depressive episodes, preventing future episodes, and reducing suicidal thoughts and behaviors, with decades of research showing that judicious use reduces suicide risk overall. Yet at the same time, mental health advocates and psychiatrists say blaming the US mental health crisis on overmedicalization and overprescription of psychiatric medications is an inaccurate portrayal. The tension reveals a genuine empirical disagreement: while doctors have typically told patients that going off SSRIs is straightforward, many patients report withdrawal symptoms. On one specific area—antidepressant use in children—there is documented peer-reviewed concern: a 2024 study found monthly antidepressant-dispensing rates for US adolescents and young adults aged 12 to 25 increased by 66.3% between 2016 and 2022, with rates 63.5% higher from March 2020 to December 2022 compared with pre-pandemic rates. The policy implications turn on how to balance this evidence: Depression remains the leading cause of disability worldwide, with only about 40% of US adults and adolescents with depression receiving counseling or therapy and just 11.4% receiving prescription medication, while the American Psychiatric Association points to structural failures like limited psychiatric beds and workforce shortages. What happens next depends on whether HHS training modules and billing changes actually improve clinical outcomes or inadvertently discourage appropriate prescribing alongside deprescribing efforts.